Trust Company of Vermont’s Aurinia Pharmaceuticals AUPH Stock Holding History

Trust Company of Vermont’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$15.9K	Hold	1,000	–	–	﹤0.01%	792
2025 Q3	$11.1K	Hold	1,000	–	–	﹤0.01%	822
2025 Q2	$8.47K	Hold	1,000	–	–	﹤0.01%	840
2025 Q1	$8.04K	Hold	1,000	–	–	﹤0.01%	792
2024 Q4	$8.98K	Hold	1,000	–	–	﹤0.01%	778
2024 Q3	$7.33K	Hold	1,000	–	–	﹤0.01%	784
2024 Q2	$5.71K	Hold	1,000	–	–	﹤0.01%	741
2024 Q1	$5.01K	Buy	+1,000	New	+$6.78K	﹤0.01%	739
2023 Q4	–	Sell	-1,000	Closed	-$7.77K	–	807
2023 Q3	$7.77K	Hold	1,000	–	–	﹤0.01%	676
2023 Q2	$9.68K	Hold	1,000	–	–	﹤0.01%	679
2023 Q1	$11K	Hold	1,000	–	–	﹤0.01%	695
2022 Q4	$4.32K	Hold	1,000	–	–	﹤0.01%	781
2022 Q3	$8K	Hold	1,000	–	–	﹤0.01%	748
2022 Q2	$10K	Buy	+1,000	New	+$11.2K	﹤0.01%	678
2022 Q1	–	Sell	-1,000	Closed	-$23K	–	339
2021 Q4	$23K	Buy	+1,000	New	+$23.7K	﹤0.01%	566
2021 Q3	–	Sell	-1,000	Closed	-$13K	–	329
2021 Q2	$13K	Hold	1,000	–	–	﹤0.01%	613
2021 Q1	$13K	Hold	1,000	–	–	﹤0.01%	604
2020 Q4	$14K	Hold	1,000	–	–	﹤0.01%	587
2020 Q3	$15K	Hold	1,000	–	–	﹤0.01%	563
2020 Q2	$16K	Hold	1,000	–	–	﹤0.01%	557
2020 Q1	$15K	Hold	1,000	–	–	﹤0.01%	600
2019 Q4	$20K	Hold	1,000	–	–	﹤0.01%	604
2019 Q3	$5K	Hold	1,000	–	–	﹤0.01%	821
2019 Q2	$7K	Hold	1,000	–	–	﹤0.01%	786
2019 Q1	$7K	Hold	1,000	–	–	﹤0.01%	750
2018 Q4	$7K	Hold	1,000	–	–	﹤0.01%	782
2018 Q3	$7K	Hold	1,000	–	–	﹤0.01%	861
2018 Q2	$6K	Hold	1,000	–	–	﹤0.01%	906
2018 Q1	$5K	Hold	1,000	–	–	﹤0.01%	818
2017 Q4	$5K	Hold	1,000	–	–	﹤0.01%	832
2017 Q3	$6K	Buy	+1,000	New	+$6.3K	﹤0.01%	779

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Trust Company of Vermont's AUPH Position: Q4 2025 in Review

Trust Company of Vermont held its Aurinia Pharmaceuticals (AUPH) position steady in Q4 2025 at 1,000 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #792.

Trust Company of Vermont first reported a position in AUPH in Q3 2017 and has held it in 31 quarters since. The position peaked at $23K in Q4 2021. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

Trust Company of Vermont held 1,000 shares of Aurinia Pharmaceuticals worth $15.9K as of Q4 2025.
Trust Company of Vermont left its Aurinia Pharmaceuticals share count unchanged in Q4 2025.
Aurinia Pharmaceuticals made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #792 holding.
Trust Company of Vermont first reported a position in Aurinia Pharmaceuticals in Q3 2017 and has held it in 31 quarters since.
Trust Company of Vermont's Aurinia Pharmaceuticals position peaked at $23K in Q4 2021.
255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.